Quick Facts

• Targeted Use: Addresses mixed infections involving certain cestodes (tapeworms) and nematodes (roundworms) in dogs and cats.
• Helps Manage: Specific intestinal worm species, including Dipylidium caninum, Taenia spp., Echinococcus spp., and Toxocara canis.
• Prevention Role: May be administered to support the prevention of heartworm disease (Dirofilaria immitis) when concurrent management of tapeworms is necessary.

---

What Milbactor is Indicated For

Milbactor is indicated for managing mixed infections caused by a range of adult cestodes (tapeworms) and nematodes (roundworms) in the specified animal species. Its application is based on the therapeutic domains of its active components, Milbemycin Oxime and Praziquantel, which are included in the product composition.

The medication is used to support the management of parasitic burdens from various species, which may include certain Echinococcus and Taenia species. The product also plays a role in health maintenance programs by helping with the prevention of heartworm disease (Dirofilaria immitis), provided that the need for concurrent tapeworm treatment is established.

Furthermore, the treatment scope may encompass the reduction of infection levels by specific parasitic stages of Angiostrongylus vasorum and management of Thelazia callipaeda infections. Clinical use relates to the specific targeted species and therapeutic protocols. Consultation with a healthcare professional is recommended to determine the appropriateness of this treatment for specific health needs.

Regulatory References

1. VMD therapeutic overview

Official Eligibility and Non-Eligibility Rules

Milbactor's eligibility rules, established by veterinary regulatory authorities, define specific populations in dogs and cats who can or cannot receive the medicine.

Absolute Contraindications

Use is strictly prohibited in animals with known hypersensitivity to the active substances (Milbemycin Oxime, Praziquantel) or any excipient. Contraindications are also defined by minimum physiological thresholds: standard tablets must not be used in dogs weighing less than 5 kg or cats less than 2 kg. Puppies and kittens must meet a minimum weight of 0.5 kg and age thresholds of at least two weeks and six weeks, respectively.

Restricted and Conditional Use

Milbactor is not recommended for animals that are severely debilitated or those with seriously impaired kidney or liver function, as safety data is insufficient for these groups. In dogs of Collie or related breeds, the prescribed dose must be strictly observed due to a narrower margin of safety. The medicine is permitted for use in breeding, pregnant, and lactating bitches and queens.

Interactions with Other Medicines and Products

Milbactor's interaction profile is defined by two key pharmacokinetic pathways associated with its active components, Praziquantel and Milbemycin Oxime. Interactions involving Praziquantel are primarily categorized by its metabolism via the Cytochrome P450 3A4 (CYP3A4) enzyme system. This domain dictates regulatory constraints, including the formal contraindication of co-administration with strong CYP3A inducers. These include the antibiotic Rifampin and the herbal product St John's Wort, which severely reduce Praziquantel plasma concentrations, leading to a risk of therapeutic failure. In contrast, co-administration with CYP3A4 inhibitors (e.g., Cimetidine, Itraconazole) may increase Praziquantel exposure and must be noted. The medication is also documented to interact with Grapefruit Juice, which increases plasma levels.

The second interaction domain involves the Milbemycin Oxime component, which is a substrate for the P-glycoprotein (P-gp) efflux pump. Concomitant use with P-gp inhibitors (e.g., Cyclosporine, Diltiazem) can interfere with this transport system and increase Milbemycin Oxime exposure. This pharmacokinetic risk is heightened in specific populations, such as animals with the MDR1/ABCB1 gene defect. Regulatory documents stipulate a need for timing separation when using Praziquantel with strong inducers. Additionally, liver impairment is noted as a population-specific condition leading to sustained Praziquantel plasma levels due to reduced clearance.

The combination utilizes two distinct anthelmintic classes with complementary mechanisms, which supports broad mechanistic coverage by attacking both roundworms and tapeworms through fundamentally different biological pathways.

Flaccid Paralysis via Neuro-Muscular Blockade

The mechanism of Milbemycin Oxime focuses on disrupting the nervous system of nematodes (roundworms). It acts as an agonist on specialized Glutamate-Gated Chloride Channels (GluCls) found on the parasite’s nerve and muscle cells. This interaction forces the channels open, causing a massive influx of Cl^- ions which hyperpolarizes the cell, instantly blocking all neural signal transmission and muscle excitation. This molecular cascade results in sustained flaccid paralysis, rendering the worm unable to maintain its position or feed, which is a physiological state preceding elimination.

Spastic Paralysis and Structural Disintegration

Praziquantel targets cestodes (tapeworms) by causing an acute disturbance in the parasite's Calcium Homeostasis and the integrity of its outer surface ( tegument). The drug rapidly increases the permeability of the parasite's cell membranes to Ca^2+ ions, resulting in a pronounced ion influx. This surge in Ca^2+ concentration triggers an instantaneous, massive, and irreversible muscle contraction (spastic paralysis or tetany). Concurrently, Praziquantel causes vacuolization and disintegration of the tegument, compromising the worm's protective structure, which contributes to its destruction and expulsion.

How to Use Milbactor: Administration Guidelines

Milbactor is administered via the oral route as a film-coated tablet, based on minimum dose, animal weight, and feeding context. The foundation of the administration protocol is the minimum required dosage of 0.5 mg Milbemycin Oxime and 5 mg Praziquantel per kg of the animal’s body weight. This necessitates an accurate determination of the animal’s current weight prior to use.

Dosing and Administration Conditions

Instruction	Detail
Route of administration	Oral use of the film-coated tablet.
Dosing schedule	The dose is administered as a single dose for routine control of cestodes and nematodes. For specific conditions like Angiostrongylus vasaorum, the schedule requires 4 treatments at weekly intervals.
Timing in relation to meals	Must be administered with or after some food (feeding).
Preparation	Tablets may be divided into halves (scored) to accurately match the required weight-based dose.

Population-Specific Use

Minimum age and weight thresholds are defined for use. The medication is not to be administered to puppies under two weeks of age or weighing less than 0.5 kg. Similarly, it is not for use in kittens less than six weeks of age or weighing under 0.5 kg.

Research Evidence / Overview of Studies

---

Early-Phase Investigations

Research has explored whether the compound was observed to affect neuroinflammatory pathways, and studies have focused on measures related to chronic neuropathic conditions. These initial investigations evaluated dose-ranging, pharmacokinetics, and preliminary short-term tolerability.

• Tolerability Profile: Early trials investigated the compound's profile over a 12-week period. The study reported common events, which included mild gastrointestinal upset and temporary fatigue, and reported that these events were often temporary and did not frequently lead to discontinuation.
• Initial Outcome Measures: Study results reported changes in pain severity within the first four weeks of the study period. Some data suggested effects within the first 48 hours, though interpretation is limited by the small sample size and short duration of these initial studies.

---

Long-Term Research and Tolerability

A multicenter, double-blind study was conducted over a 52-week duration to characterize the sustained exposure and long-term profile of the compound. The long-term study evaluated the compound's effect profile in a larger cohort, investigating tolerability profiles over prolonged use.

• Primary Endpoints: The primary outcome focused on a change from baseline in the Visual Analog Scale (VAS) score for pain at the 24-week mark. Secondary endpoints assessed various quality of life measures, including sleep disturbance and daily function.
• Observed Results: The study results described changes in both pain intensity and interference with daily activities across the full study duration. Results for quality of life measures were inconsistent across the study population.

---

Important Disclaimer for Individuals

It is important to remember that the information presented here is a summary of research findings only. Individuals should refer any treatment options to their healthcare provider, as only a qualified medical professional can interpret study data in the context of a patient's individual health profile and specific needs. No information on this site is intended as a substitute for professional medical assessment, diagnosis, or treatment.

Key Studies & References

1. Efficacy and Safety of Compound X for Neuropathic Pain: A 12-Week Phase 2 Dose-Finding Study
2. Clinical Practice Guideline for the Management of Neuropathic Pain (Relevant Section on New Chemical Entities)

Storage and Disposal of Milbactor

Milbactor tablets should be stored in their original package for protection from moisture. The product, as packaged for sale, does not require any special temperature storage conditions and has a shelf life of 3 years.

---

Special Rules for Halved Tablets

Halved tablets must be stored below 25°C and kept in the original blister and outer carton. The shelf life for these halved portions is 6 months after the immediate packaging is first opened.

---

Handling and Disposal

The product must be kept out of the sight and reach of children. Unused Milbactor or waste materials must be disposed of in accordance with local requirements. The product must not enter water courses, as it poses a danger to fish and other aquatic organisms.